Japan’s first X-ray CT equipped with a photon counting detector installed at the Advanced Medical Development Center of the National Cancer Center
Last year, Canon Inc. (hereafter, Canon) acquired Redren Technologies, Inc. (hereafter, Redren), which has world-class technology in the development and manufacture of semiconductor detector modules (*1). Canon Medical Systems Inc. (hereafter, Canon Medical), a group company, has developed the first domestically produced X-ray CT (*3) equipped with a photon-counting detector that utilizes Redren’s technology (*3). CT, hereinafter referred to as PCCT) was developed and established at the National Cancer Center Advanced Medical Development Center (hereinafter referred to as National Cancer Center Advanced Medical Development Center). As a result, research for future practical use has started.
The PCCT is equipped with a high-quality, state-of-the-art modular photon-counting detector that utilizes the crystal
fabrication/processing techniques that produce Redren’s detector materials. By adopting a modular type, it is possible to expand the detector size and reduce manufacturing and service costs. It is expected that this will enable testing that meets all clinical needs. [Image 1
Researcher at National Cancer Center Hospital East
Canon Medical, the National Cancer Center Advanced Medical Development Center, and the National Cancer Center Hospital East, based on the comprehensive agreement (*4) concluded in July 2020 and the basic joint research agreement concluded in November of the same year, PCCT We have already started joint research (*5) for the practical application of this technology. It reports performance improvements. In the future, we will explore new value in a wide range of clinical areas using PCCT and aim for early practical application.
Unlike indirect X-ray detection using conventional scintillator-type detectors, PCCT can detect X-rays directly using a photon-counting detector, which is expected to improve basic performance. For example, examination with lower exposure dose than conventional equipment, improvement of detection ability of lesions due to high-definition images, discrimination of multiple substances in the body, evaluation of properties and malignancy of tumor tissue with excellent
quantitative images, etc. It is expected to improve diagnostic accuracy from prevention and diagnosis to treatment effect judgment and prognosis evaluation.
Dr. Tatsuji Kobayashi, head of the Department of Diagnostic Radiology at the National Cancer Center Hospital East, said, “Canon’s CT has already achieved a high level of definition. It may be possible to provide visually easy-to-understand images by qualitative diagnosis to differentiate malignancy and imaging of treatment effects with anticancer drugs, etc. In addition, regular CT scans are performed for postoperative follow-up of cancer. We expect that PCCT’s exposure dose reduction will reduce the medical radiation exposure of patients and allow them to undergo examinations with peace of mind.”
Toshio Takiguchi, Canon Senior Managing Executive Officer and President and CEO of Canon Medical, said, “By commercializing next-generation PCCT that combines Redren’s technology with Canon Medical’s unique technology such as AI image reconstruction and analysis technology, we will achieve the No. 1 global market share for CT. In addition, Canon will contribute to the development of diagnostic imaging technology by supplying Redren’s photon counting detectors to medical device manufacturers around the world.” I’m here. Going forward, Canon will continue to strengthen its medical business, one of its new businesses, and strive for new growth while continuing to contribute to healthcare around the world.
*2.: As of November 6, 2022. Canon research.
*3. : Not approved for medical devices.
*4. : https://jp.medical.canon/News/PressRelease/Detail/61759-834 *5. : https://jp.medical.canon/News/PressRelease/Detail/107617-834 Details about this release: